Kiadis Pharma has expanded its presence in the US, with the new Chief Financial Officer (CFO) and new Senior Vice President (VP) of corporate affairs both based in Boston. Scott Holmes will take on the role of CFO, and Amy Sullivan will be the new Senior VP.
Kiadis is a biopharmaceutical company working on its cell-based immunotherapy platform. With multiple pipeline projects, they are building to become a fully integrated company.
Both appointments are to positions key to the Biopharmaceutical company’s interface with the financial market. The Dutch-based company expects their location in the US to contribute to an increased US market presence.
Holmes will commence his appointment that was announced mid-2018, starting at the same time as Sullivan.
Sullivan holds degrees in science in business and business administration and has over 25 years experience within biotechnology and life sciences brands on a corporate level, coming from the same role with Karyx Biopharmaceuticals. In her time there she was responsible for all investor, corporate and public communication throughout the commercialization of the company’s first FDA-approved medicine and, ultimately, a merger.
Commenting on the appointments, Arthur Lahr, Kiadis CEO, said: “They are a strong team and together bring a wealth of capital markets experience and strong relationships with the financial community to our company.”
